Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Ad-vanced and Metastatic Esophageal Squamous Cell Carcinoma: a real world experience

<p><strong>Figure S1 the detail of treatments.</strong> Blue arrow means this patient was still alive at the latest date of follow up. Hollow circle means this patient die. The others were lose follow up at the latest date of follow up.</p> <p><strong>Figure S2 progression free survival (PFS) of patients received immunotherapy, including 5 nivolumab and chemotherapy and 1 dual immune check point inhibitor, on different PD-L1 tumor cells (TC) expression.</strong> (A) divided by PD-L1 TC &lt;1% or ≧1%. (B)divided by PD-L1 TC &lt;10% or ≧10%.</p>